Ken Steadman, PhD

Ken Steadman, PhD has over 20 years of work experience in various scientific roles. Ken is currently working as a Principal Scientist at Plexium since January 2021. Prior to that, they worked at Cedars-Sinai for 7 years as a Doctoral Candidate, where they completed their doctoral dissertation on ONECUT2 and its role in driving aggressive prostate cancer. Their work has been published in reputable scientific journals and they are an inventor on a pending patent.

Before Cedars-Sinai, Ken worked at Georgetown University for 6 years, initially as a Research Associate and later as a Lab Manager. Ken also worked at the National Cancer Institute for 4 years in various roles including Pre-Doctoral Fellow, Post-Baccalaureate Fellow, Guest Researcher, and Summer Research Intern. Their early experience includes working as a Laboratory Technician at George Mason University.

Overall, Ken Steadman, PhD has a strong background in scientific research, with expertise in oncology and prostate cancer.

Ken Steadman, PhD completed their Bachelor of Science (B.S.) degree in Biology from George Mason University. Afterward, they pursued further education at Cedars-Sinai Medical Center, where they obtained their Doctor of Philosophy (PhD) in Biomedical Science and Translational Medicine from 2013 to 2020.